Ligand price target raised to $206 from $157 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ligand (LGND) to $206 from $157 and keeps a Buy rating on the shares based on upward adjustments to the firm’s Filspari sales projections after partner Travere (TVTX) announced that the FDA approved an update to the REMS labeling for the drug. The firm also cites adjustments to its underlying assumptions for Ligand’s later stage partnered assets.